Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Huttner A, Agnandji ST, Engler O, Hooper JW, Kwilas S, Ricks K, Clements TL, Jonsdottir HR, Nakka SS, Rothenberger S, Kremsner P, Züst R, Medaglini D, Ottenhoff T, Harandi AM, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Among authors: engler o. Clin Microbiol Infect. 2023 Dec;29(12):1587-1594. doi: 10.1016/j.cmi.2023.08.026. Epub 2023 Sep 3. Clin Microbiol Infect. 2023. PMID: 37661067
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.
Pejoski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medaglini D, Pozzi G, Vono M, Lambert PH, Huttner A, Haks MC, Ottenhoff THM, Villard J, Siegrist CA; VEBCON Consortium; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium. Pejoski D, et al. NPJ Vaccines. 2020 Apr 14;5(1):32. doi: 10.1038/s41541-020-0179-4. eCollection 2020. NPJ Vaccines. 2020. PMID: 32337075 Free PMC article.
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.
Vianello E, Persson J, Andersson B, van Veen S, Dias TL, Santoro F, Östensson M, Obudulu O, Agbajogu C, Torkzadeh S; VSV-EBOVAC; VSV-EBOPLUS Consortia; Nakaya HI, Medaglini D, Siegrist CA, Ottenhoff THM, Harandi AM. Vianello E, et al. iScience. 2023 Nov 23;26(12):108574. doi: 10.1016/j.isci.2023.108574. eCollection 2023 Dec 15. iScience. 2023. PMID: 38162033 Free PMC article.
Presence and Persistence of Andes Virus RNA in Human Semen.
Züst R, Ackermann-Gäumann R, Liechti N, Siegrist D, Ryter S, Portmann J, Lenz N, Beuret C, Koller R, Staehelin C, Kuenzli AB, Marschall J, Rothenberger S, Engler O. Züst R, et al. Among authors: engler o. Viruses. 2023 Nov 17;15(11):2266. doi: 10.3390/v15112266. Viruses. 2023. PMID: 38005942 Free PMC article.
The WHO BioHub system: experiences from the pilot phase.
Brackmann M, Zysset D, Liechti N, Hunger-Glaser I, Engler O. Brackmann M, et al. Among authors: engler o. BMJ Glob Health. 2023 Aug;8(8):e013421. doi: 10.1136/bmjgh-2023-013421. BMJ Glob Health. 2023. PMID: 37558272 Free PMC article. No abstract available.
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants.
Rothenberger S, Hurdiss DL, Walser M, Malvezzi F, Mayor J, Ryter S, Moreno H, Liechti N, Bosshart A, Iss C, Calabro V, Cornelius A, Hospodarsch T, Neculcea A, Looser T, Schlegel A, Fontaine S, Villemagne D, Paladino M, Schiegg D, Mangold S, Reichen C, Radom F, Kaufmann Y, Schaible D, Schlegel I, Zitt C, Sigrist G, Straumann M, Wolter J, Comby M, Sacarcelik F, Drulyte I, Lyoo H, Wang C, Li W, Du W, Binz HK, Herrup R, Lusvarghi S, Neerukonda SN, Vassell R, Wang W, Adler JM, Eschke K, Nascimento M, Abdelgawad A, Gruber AD, Bushe J, Kershaw O, Knutson CG, Balavenkatraman KK, Ramanathan K, Wyler E, Teixeira Alves LG, Lewis S, Watson R, Haeuptle MA, Zürcher A, Dawson KM, Steiner D, Weiss CD, Amstutz P, van Kuppeveld FJM, Stumpp MT, Bosch BJ, Engler O, Trimpert J. Rothenberger S, et al. Among authors: engler o. Nat Biotechnol. 2022 Dec;40(12):1845-1854. doi: 10.1038/s41587-022-01382-3. Epub 2022 Jul 21. Nat Biotechnol. 2022. PMID: 35864170 Free PMC article.
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
Jonsdottir HR, Siegrist D, Julien T, Padey B, Bouveret M, Terrier O, Pizzorno A, Huang S, Samby K, Wells TNC, Boda B, Rosa-Calatrava M, Engler OB, Constant S. Jonsdottir HR, et al. Among authors: engler ob. Biomed Pharmacother. 2022 Jun;150:113058. doi: 10.1016/j.biopha.2022.113058. Epub 2022 May 2. Biomed Pharmacother. 2022. PMID: 35658229 Free PMC article.
49 results